Engitix Therapeutics

We are delighted to announce the appointments of Adrian Ray and Scott Turner as Scientific Advisors. Dr Giuseppe Mazza CEO said: “We are pleased to welcome Dr Adrian Ray and Dr Scott Turner, as new scientific advisors. Their combined industry insights, strong translational science and small molecule and biologic drug discovery experience across cancer and fibrosis will enhance our R&D efforts. Their strategic guidance will be invaluable as we continue to advance discoveries from our proprietary ECM platform technologies into transformational therapies for patients with fibrosis and solid tumours.” Dr Adrian Ray has over two decades of experience in biotech working at Gilead, Nimbus, Morphic and, most recently, serving as Chief Scientific Officer at Third Harmonic Bio. He has provided leadership for small molecule drug discovery, nonclinical development and translation across therapeutic areas contributing to numerous IND and successful worldwide registrational filings. Dr Scott Turner is currently the Chief Scientific Officer at Arda Therapeutics. Prior to joining Arda, Scott served as CSO at Pliant Therapeutics, where he played a pivotal role in the creation of Pliant's fibrosis discovery platform and spearheaded the development of their anti-fibrotic pipeline. His innovative approaches, including pioneering the use of single-cell data to dissect drug mechanisms of action and driving an advanced biomarker strategy, led to remarkable successes in achieving clinical proof of concept. Prior to Pliant, Dr Turner led research and development at KineMed Inc. a platform technology company developing translational biomarkers in fibrosis and metabolic disease. Scott and Adrian join our strong advisory network of renowned global academics and clinical leaders specialising in diseases of the gastrointestinal system, skin and lung fibrosis, and cancers. Current scientific advisors also include Massimo Pinzani, Alexey "Alex" Lugovskoy, Doug Thorburn, Emmanuel Tsochatzis, Tu Vinh Luong, Antonio Di Sabatino, Hendrik-Tobias Arkenau & Giuseppe Kito Fusai. See the full press release HERE: https://lnkd.in/eNdR_uGs #ScientificAdvisors #EngitixTherapeutics #DrugDiscovery #ECM

Copenhagen will host the ECM2024 Pharmacology Congress next week, featuring a great program and speakers' lineup focused on exciting updates about the role of ECM in various disorders and its potential as a source of therapeutic targets and biomarkers. We are thrilled to have our CEO Giuseppe Mazza present Engitix Therapeutics’ work on decoding our unique ECM platform to develop novel therapies for fibrosis and solid tumours. Join him next Monday at 1:10PM CEST! #ECM #TheECMCompany #ECM2024 #fibrosis #solidtumours

We're excited for Alan Holmes, our VP of Translational Biology, to be presenting at the EASL the home of Hepatology symposium in Milan later today. Reach out to him to learn more about Engitix!

We are excited about the journey so far and are very much looking forward to what’s coming next as we head towards pre-clinical development! Find out more about Engitix's mission to develop therapies for patients with fibrosis and cancer. Take an in-depth look into our research, which involves our world-leading ECM platform, passionate team, and impactful discovery projects, through our new introduction video. 📽 🔬 #EngitixTherapeutics #DrugDiscovery #ECM #Team https://lnkd.in/eHmMaRCq

We are delighted to announce the appointments of Matthew Edwards, Ph.D., as Senior Vice President of Discovery Sciences at Engitix, and Bevan Emma Huang, Ph.D., as Vice President of Data Sciences. Dr. Edwards is a seasoned drug discovery leader with extensive industry experience. He has developed six clinically-enabled novel therapeutics and has deep expertise in immunology and oncology. Previously, he was the Global Head of Discovery and Translational Sciences for Interventional Oncology at Johnson & Johnson, where he developed a portfolio of intra-tumorally delivered immuno-oncology assets. He also held leadership positions at Novartis and GSK in respiratory and immunology therapeutics. At Engitix Therapeutics, he will lead the company’s internal drug discovery scientific strategy. Dr. Huang brings a strong track record in data science, accelerating the development of novel therapies. At Johnson & Johnson, she was Head of Data Sciences for Interventional Oncology, where she built key data science capabilities to support discovery and translational biomarker efforts. With over 40 peer-reviewed papers and experience across academia, government, and industry, Emma has shown her commitment to scientific advancement. At Engitix Therapeutics, she will lead the company’s data and analytics strategy, supporting platform development, internal drug discovery, and external partnerships. Welcoming them to Engitix Dr Christopher Stevenson CSO said, “I am delighted to welcome Matt and Emma to Engitix. We have created the roles of SVP Discovery and VP Data Sciences to expand our leadership team and capabilities. The expertise Matt and Emma bring will galvanise the team’s focus on translating the insights gained from Engitix’ proprietary platform technologies into transformational therapies for patients.” See the full press release HERE: https://lnkd.in/eGpscvSq #appointments #EngitixTherapeutics #drugdiscovery #ECM #inflammation #fibrosis #cancer

Today is #WorldLiverDay, and this year's theme, « Keep your liver healthy and disease-free » emphasizes the importance of regular health check-ups in preventing liver-related disorders. With remarkable breakthroughs, such as the FDA's approval of the first NASH drug and promising results in combating obesity and liver damage with GLP1 agonists, there's much optimism. Despite these achievements, liver fibrosis remains a significant medical challenge. At Engitix, we are dedicated to tackling this issue by decoding the human extracellular matrix in healthy and diseased organs to identify novel anti-fibrotic therapies. Our efforts align with the broader goal of preventing and curing liver diseases, which claim 2 million lives annually and account for 4% of global deaths. Leveraging our distinctive translational capabilities, we directly assess the biology of fibrotic tissues to uncover groundbreaking therapeutic strategies. Our team is committed to expediting the transition of these transformative therapies from development to clinical application. We extend our gratitude to our partners and collaborators for their unwavering dedication to realizing this vision. #people #liverhealth #liverfibrosis #theecmcompany

We recently had the pleasure of hosting Andrea Beccari from Dompé, at our London facility, where he delivered an incredibly insightful lecture on the role of synthetic data and super computing power for developing new therapeutics . Thank you for traveling all the way from Italy to share your expertise with our team. With a background deeply rooted in pharmaceutical research and a wealth of experience spanning leadership positions at Dompé, Andrea has been at the forefront of designing and developing their groundbreaking AI-driven drug discovery platforms. His visionary leadership as Vice President of EXSCALATE is shaping the future of drug discovery, leveraging machine learning and molecular simulations. Andrea's impressive academic achievements, including over 65 publications and co-invention of more than 15 patents, speak volumes about his dedication to advancing the field. Engitix and Dompé Farmaceutici have been working in partnership for more than two years; uniting the strengths of EXSCALATE, Dompé’s AI supercomputer structure-based drug design platform, with Engitix’s patient-centric ECM platform and deep understanding of the human ECM to deliver small molecule therapeutics to improve the lives of patients with fibro-inflammatory disorders. We are excited to continue our collaboration to further explore the frontiers of healthcare innovation together! #AI #drugdiscovery #ecm #fibrosis

We’re really excited to share that we’ve been featured on the Sifted 100 UK & Ireland Leaderboard 💯 🚀🥼 This inaugural ranking showcases the top 100 fastest-growing startups across the UK and Irish ecosystems. Want to see who else made the cut? Check out the leaderboard: https://lnkd.in/d-6Nq7Km m_campaign=sifted100leaderboard&utm_content=startups Or download Sifted’s report to read more about us: https://lnkd.in/dj37xi7h rce=linkedin&utm_campaign=sifted100report&utm_content=startup #healthtech #theECMcompany #drugdiscovery #team

On #InternationalWomensDay, we celebrate the remarkable contributions of women worldwide. Today, let's reflect on our ongoing efforts to cultivate a culture that empowers women to thrive limitlessly.  #investinwomen #genderequity #iwd2024

A million thanks to Alexey "Alex" Lugovskoy for making the trip from Boston to share his insights by giving an enlightening lecture to our team. Alex is a co-founder and CEO of Diagonal Therapeutics and an Entrepreneur-in-Residence at Atlas Venture. His passion for discovering new therapies and biotechnology experience has inspired us. Throughout his impressive career, Alex has held leadership roles in many biotech companies, including Dragonfly Therapeutics and Morphic Therapeutic. His expertise, evidenced by over 100 patents and manuscripts, has greatly enriched our understanding of the critical ingredients required to succeed in our field. We're reminded that "It's the implementation that counts," which means putting plans into action matters most. Success comes from i) setting the right strategy, ii) accurate planning of programs, prioritizing key value-building activities, and iii) executing the work promptly with collaborative, talented, and passionate people. We, at Engitix, are moving from being a platform company to a multi-assets preclinical stage biopharma. We've set the strategy for our next phase, and now it's all about making it happen! #theECMcompany #Engitix #teamwork